Du är här


CellaVision AB: Bulletin from the Annual General Meeting of CellaVision AB (publ) held on May 7, 2014

CellaVision AB (publ) held its Annual General Meeting today, 7 May 2014, in
Lund. The meeting resolved upon the following:

* Payment of dividend in the amount of SEK 0.50 per share with 12 May 2014 as
record date, meaning that payment is expected to be made on 15 May 2014.
* Discharge from liability for the members of the Board of Directors and the
President and CEO.
* Re-election of Lars Gatenbeck, Christer Fåhraeus, Torbjörn Kronander, Anna
Malm Bernsten och Roger Johanson as members of the Board of Directors.
Election of Niklas Prager as a new member of the Board of Directors.
Re-election of the auditor.
* Resolution on remuneration for the members of the Board of Directors and
the auditor.
* Resolution on an incentive program for the company management. Those
eligible are the CEO and members of the executive management.

More detailed information concerning the resolutions passed at the general
meeting of shareholders is available in Swedish only.

CEO Yvonne Mårtensson's address to the meeting is available at the Investor
pages at CellaVision's website

For more information, please contact:

Lars Gatenbeck, Chairman of the Board, CellaVision AB.

Phone: +46 70 535 44 44, e-mail:lars.gatenbeck@lifemedical.se

Yvonne Mårtensson, CEO, CellaVision AB.
Phone: +46 708 33 77 82, e-mail:yvonne.martensson@cellavision.com
About CellaVision
CellaVision is an innovative, global medical technology company that develops
and sells its own leading systems for routine analysis of blood and other
body fluids in health care services. The products rationalize manual
laboratory work, and secure and support effective workflows and skills
development within and between hospitals. The company has leading-edge
expertise in image analysis, artificial intelligence and automated
microscopy. In most countries sales are via global partners. Products are
sold directly in the Nordic countries and via subsidiaries in the US, Canada
and Japan. In 2013 sales were SEK 180 million and sales continue to increase,
with a growth target of at least 15 % per year over an economic cycle.
CellaVision's registered office is in Lund, Sweden. The share is listed on
the Nasdaq OMX Stockholm, Small Cap list. Read more atwww.cellavision.com.


This information was released for public disclosure on May 8, 2014 at 08.30

Press release as PDF


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: CellaVision AB via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.